Clinical Trials Summary for out of hours Important Reference



Acronym study title	ELEGANT STML-ELA-0422 Study
Study Details	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Principal Investigator PI Sub PI's	PI – Dr Martin Hogg Sub Investigator – Dr Parth Desai & Dr Elaine Young
Research Nurse Team	Research Nurse – Haiyan Huang CTSO - Bethany Webster
Drug therapy	Randomised to either Elacestrant or SoC endocrine monotherapy
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams